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HIV infection of the central nervous system occurs 
almost simultaneously with systemic infection. Pri-
mary neurological disorders can affect the brain (e.g. 
HIV-associated dementia), spinal cord (e.g. HIV- asso-
ciated vacuolar myelopathy) and meninges.1 HIV-as-
sociated dementia (HAD) has also been referred to as 
HIV encephalopathy or AIDS dementia complex. These 
terms have been used interchangeably and describe a 
syndrome that includes the symptom triad of psycho-
motor slowing, memory impairment and behavioural 
problems. We now understand that neurocognitive im-
pairment (NCI) in HIV is a spectrum of disorders.2 In 
addition to HAD, lesser forms of NCI have also been 
described, namely HIV-associated minor cognitive-
motor deficit (now called mild neurocognitive disorder) 
and  asymptomatic neurocognitive impairment (ANI).3 
These disorders now fall under the new term HIV-as-
sociated neurocognitive disorder (HAND) (Table I). The 
diagnosis of HAND requires a history, clinical examina-
tion, appropriate investigations and neuropsychologi-
cal testing. This review presents the clinical features, 
diagnostic criteria and tools to help diagnose HAND. 
HIV neuropathogenesis is not fully understood. It is un-
clear whether the cognitive decline seen in HIV-infected 
people is partly or wholly due to the direct effects of HIV, 
to secondary effects from the chronic hyperimmune ac-
tivation, to other immunological factors (e.g. cytokines, 
chemokines and tumour necrosis factor) in the CNS, or 
to other factors such as hepatitis co-infection and clade 
diversity. However, it is understood that:4 
n  HIV does not infect the neurons and oligodenro-
cytes but the monocytes, microglia, astrocytes and 
endothelial cells. 
n  Once in the CNS the virus persists and evolves into 
different strains independent of the systemic res-
ervoir. 
n  HIV is not evenly distributed in the CNS, and has a 
predilection for the basal ganglia.
n  HIV RNA levels in the cerebrospinal fluid do not 
correlate with those in the peripheral circulation, 
especially in advanced HIV disease.
Involvement of the basal ganglia accounts for the clini-
cal distinction between ‘subcortical dementia’ seen in 
HAD and the ‘cortical dementia’ typically seen in Alz-
heimer’s disease. 
HAD occurs in approximately 10 - 15% of all individu-
als with HIV/AIDS and is more common in late stages 
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Neurocognitive impairment (NCI) occurs in 10 - 60% of people living with HIV/AIDS (PLWHA), depending on the 
severity of the NCI and the stage of the disease. The clinical features and definitions have evolved over the past two 
decades. HIV-associated neurocognitive disorder (HAND) is a new term used to describe the spectrum of neuro- 
cognitive impairment seen in HIV/AIDS. The earliest to most advanced stages are asymptomatic neurocognitive 
impairment (ANI), minor neurocognitive disorder (MND) and HIV dementia (HAD), respectively. People with HAND 
have impairment on multiple cognitive domains, including attention, concentration, memory, executive function, 
motor functioning and speed of information processing, and sensory perceptual/motor skills deficits. The milder 
forms of HAND are easily missed. Diagnosis can be made on clinical grounds in the most severe cases; however, 
milder forms and confirmation of the diagnosis require neuropsychological testing. Screening tests have limited 
utility, especially in the milder forms of HAND. Individual subtests derived from longer neuropsychological batter-
ies may be complementary in the diagnosis of HAND. Highly active antiretroviral therapy (HAART) has led to a 40% 
decline in the incidence of HAD. In the post-HAART era, HAD runs a more chronic course, is milder and is reversed 
in about a third of cases. However, HAART is not universally successful because incident cases occur in people on 
HAART. Overall HAART has been shown to be of benefit, and screening for HAND should be the standard of care for 
PLWHA. HAD is an AIDS-defining illness and patients qualify for HAART irrespective of their CD4 count. However, 
the benefit of starting ARVs for people with ANI and MND is currently inconclusive. 
PatHOGeneSiS ePidemiOlOGY
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of infection.1 Less severe forms of HAND occur in 30 
- 60% of people infected with HIV, depending on the 
stage of the disease.1 Approximately 17% of the peo-
ple attending a highly active antiretroviral therapy 
(HAART) primary health clinic in Cape Town had some 
level of NCI, including HAND.5 The epidemiology of NCI 
has changed distinctly with the introduction of HAART. 
In the pre-HAART era HAD was common and more se-
vere, with death likely within 6 months of diagnosis.6 
The introduction of HAART led to a major decline in 
the incidence of HAD.1,6,7 However, data from cohorts 
on long-term HAART in the USA show that incident 
cases of HAD occur despite HAART, that progression 
of HAD is variable, and that NCI seems to be milder.1 
The overall prevalence of HAND continues to rise, pre-
sumably owing to incomplete reversal or prevention of 
cognitive impairment, longer survival on HAART and an 
increasing HIV prevalence. 
At present there are no guidelines that recommend 
specific HAART regimens for the treatment or preven-
tion of HAND. However, epidemiological data suggest 
at least partial benefit in giving HAART to prevent and 
reverse HAND.7-9 HAD is an AIDS-defining illness and 
people with HAD qualify for HAART irrespective of 
CD4 counts. There is therefore an urgent need to raise 
awareness and develop rapid screening tools to detect 
and monitor HAND. 
Most clinicians can recognise frank HAD, but the more 
subtle HANDs are easily missed. HAND is: (i) a cognitive 
disorder, accompanied by (ii) motor dysfunction and/or 
(iii) behaviour problems. 
Cognitive changes are problems with memory, de-
creased attention and concentration. These patients 
have decreased ability to learn new information and 
the speed at which they process information and men-
tal tasks is slower than normal. Executive functioning, 
which includes planning, impulse control, organisation, 
abstract thinking and judgement, is also affected.
Motor changes are more subtle and are often missed. 
Patients complain of changes in their handwriting, 
tremor, and ‘clumsiness’. They have gait abnormalities 
in the late stages. 
Behaviour problems vary and range from aggression 
or marked isolation to the vegetative state seen in the 
late stages when patients are mute, immobile and in-
continent. The presentation is similar to that of severe 
depression, because patients appear very apathetic and 
amotivated, with lack of initiative and psychomotor 
slowing.
The new classification requires systematic assessment 
of the following six domains:3 (i) attention-informa-
tion processing; (ii) language; (iii) abstraction/execu-
tive; (iv) complex perceptual motor; (v) memory; and 
(vi) sensory perceptual/motor.
Assessment of these domains requires neuropsycho-
logical tests that are often not intuitive to the clini-
cian. Most clinicians can test memory with ‘bedside’ 
tests; however, assessment of executive functioning 
and psychomotor speed is more difficult. The challenge 
is to translate these research criteria and recommend 
specific tests that can be widely used by non-neu-
ropsychologists. We can recommend a few tests that 
can assess these various domains (Table II). 
The distinction between ANI, MND and HAD depends 
on: (i) the severity of impairment (when compared with 
population age- and education-appropriate norms for 
the above domains); and (ii) level of functional impair-
ment in everyday activities at work, home or socially.
 asymptomatic neurocognitive  minor neurocognitive  HiV-associated   
 deficit (ani)  disorder (mnd)  dementia (Had)
Level of impairment None  Mild everyday activities: reduced  Marked impairment in 
mental acuity, inefficiency in work,  day-to-day activities 
homemaking or social activities  at work, home or 
affected social functioning
Number SD below  1  2 
population norm on  
neuropsychological test
Number of domains  2 
impaired  Attention/working memory; verbal/language; abstraction/executive; complex perceptual motor; 
memory (learning and recall); speed of information processing; sensory perceptual/motor skills
Exclusion criteria  Absence of criteria for delirium or other causes for dementia. The condition cannot be explained by 
another co-morbid condition, e.g. substance abuse, infections, pre-existing neurological condition 
*Summarised from Antinori et al.3
taBle i. cRiteRia FOR HiV-aSSOciated neUROcOGnitVe imPaiRment*
clinical FeatUReS
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aSYmPtOmatic neUROcOGnitiVe imPaiRment
This is the mildest form of HAND. The person has no 
impairment in everyday activities. They may complain 
of mild slowing in mental acuity and loss of concentra-
tion. Abnormalities can only be detected by testing the 
six domains and comparing against population norms. 
Patients must have 1 standard deviation (SD) abnor-
mality on two of the six domains. ANI can progress to 
the next stage in the spectrum of HAND. 
minOR neUROcOGnitiVe diSORdeR
MND was previously called HIV- associated minor mo-
tor-cognitive disorder. MND has the same criteria as 
ANI, i.e. the patient has 1 SD abnormality on two of 
the six domains. Unlike patients with ANI, they have 
impairment in their daily activities, at work or in social 
functioning or homemaking. This can be by self-report 
or by observation by someone who knows the patient. 
HiV-aSSOciated dementia
HAD is the most severe form of HAND. By definition pa-
tients have at least 2 SD abnormality on two domains, 
and these deficits cause significant impairment in eve-
ryday activities.3 However, the clinical presentation can 
vary widely. In early HAD, the patient may appear de-
pressed with apathy, lethargy and social withdrawal. 
Personality changes are not uncommon, and are often 
reported more by others than by the patient. In late 
HAD, psychotic symptoms may be prominent along 
with severe language dysfunction, verbal memory loss, 
seizures and mutism. The patient may be incontinent 
of urine and stool.
Neurological examination may show interruption of 
smooth ocular pursuit, slowing or inaccuracy of sac-
cades, hyper-reflexia, ‘frontal release’ signs, slowing of 
rapid alternating movement of fingers, wrist or feet, 
and ataxia. 
In the post-HAART era the progression of HAD has 
changed. Based on clinical observation of long-term 
treatment cohorts, three sub-types of HAD have been 
defined:7
1.    Sub-acute progressive dementia occurs in ARV-
naïve people and has a course similar to that ob-
served in the pre-HAART era.
2.    Chronic active dementia. These patients are on 
treatment but have poor adherence leading to vi-
ral resistance. They are at risk of developing other 
neurological complications. 
3.    Chronic inactive dementia occurs in people who 
are adherent to HAART and have undetectable vi-
ral loads. They have some recovery from neuronal 
injury and are neurologically stable. 
HAND is a diagnosis of exclusion. Other diseases that 
affect CNS functioning, i.e. opportunistic infections, 
neoplasms, metabolic disturbances and iatrogenic 
complications, have to be systematically ruled out. De-
lirium and substance use are common in HIV-infected 
patients. Appropriate first-line investigations, e.g. a 
full blood count, assessment of kidney, liver and thy-
roid function, measurement of the vitamin B12 level and 
serological testing for syphilis, are necessary. Lumbar 
puncture is also useful to exclude other opportunistic 
infections. The CSF viral load is not useful in the diag-
nosis of HAND and does not correlate with the severity 
of the impairment. Neuro-radiological investigations, 
e.g. computed tomography and magnetic resonance 
imaging, are necessary to exclude conditions such as 
progressive multifocal leuco-encephalopathy and pri-
mary CNS lymphomas that can mimic HAND. However, 
in resource-constrained settings these investigations 
are not readily available and they are not vital in the 
absence of focal localising signs. 
With delirium and medical causes excluded, the diagnosis 
of HAND requires testing of the six domains using neu-
ropsychological tests. However, these are often imprac-
tical or not available in busy clinical settings. Two-stage 
clinical WORK-UP FOR Hand
Neuropsychological test Description Domains assessed
Rey Auditory Verbal Learning Test Recall as many words as possible from a list of 15 words Memory
Grooved peg-board  Motor
Digit span forward Patient is given an increasing number of random digits.  Attention and concentration 
 They must repeat digits in the same order
Digit span backward Patient is given an increasing number of random digits.  Attention, concentration 
 They must repeat the digits in reverse order and working memory
Trail making test A Join 25 circles with numbers in the correct sequence as  Motor and speed of 
 quickly as possible. The numbers are distributed across the  information processing 
 page and are not in order
Trail making test B Join 25 circles with numbers and letters in alternating  Motor and speed of 
 sequence, i.e. join 1, A, 2, B, 3, C as quickly as possible  information processing and 
executive function
taBle ii. Selected neUROPSYcHOlOGical teStS and tHe dOmainS aSSeSSed
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testing is commonly used in psychiatry. In the first stage 
a brief, bedside cognitive screening test is administered 
and people who screen positive can then be subjected 
to more detailed testing in the form of a neuropsycho-
logical battery. See Fig. 1 for algorithm for assessing and 
managing newly diagnosed patients with HIV.  
cOGnitiVe ScReeninG WORK-UP
The Mini-Mental State Examination (MMSE) was 
validated for distinguishing Alzheimer’s dementia from 
other dementing disorders.10 It is loaded with items that 
are representative of ‘cortical’ functions. Since HAND is 
primarily affects sub-cortical processes, the MMSE is 
not ideal. It is not useful in detecting the milder forms 
of HAND, and it is affected by age, education and cul-
tural background.11
The HIV Dementia Scale comprises four items – an 
anti-saccadic eye movement error task, timed alpha-
bet, verbal memory and copying a cube.12 Two of these 
items are timed and therefore more sensitive to sub-
cortical functions. This scale has been used in the USA13 
and validated in South Africa.5 However, observing the 
anti-saccadic eye movement requires training and is 
difficult for non-neurologists to administer.14
Mental alternation test. Patients are asked to count 
to 20, say the alphabet, and then alternate between 
the numbers and letters in the following fashion: ‘1-A, 
2-B, 3-C ...’. Progressing from the most recent number 
or letter to the next letter or number in the sequence 
is one alternation. The number of correct alternations 
in 30 seconds, discounting any errors, determines the 
Fig. 1. Summary assessment and management of neurocognitive function in newly diagnosed PLWHA. 
Fig. 1. Summary assessment and management of neurocognitive function in newly diagnosed PLWHA.
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score. The maximum score is 52 points, and a score of 
≤15 indicates the need for more extensive cognitive 
testing. This tests a limited number of cognitive do-
mains and is dependent on level of education.15 
international HiV dementia Scale (iHdS). The IHDS 
was tested in the USA and Uganda and developed spe-
cifically for resource-constrained settings.14 It has three 
subtests: timed alternating hand sequence, timed fin-
ger tapping, and recall of four items after two minutes. 
This test has many advantages over its predecessors: 
it is brief, it can be completed in 2 - 3 minutes, and 
the patient does not need knowledge of English. It can 
be performed by non-neurologists and does not require 
any special equipment other than a stop-watch. The 
recommended cut-off score of 10 had 80% sensitivity 
and 55% specificity in the Ugandan study.14 The spe-
cificity declines rapidly with small increment changes 
in the score, and this may limit its utility. While it has 
many advantages, validation studies are needed for our 
local population. 
Neuropsychological battery. Various neuropsycholog-
ical test batteries have been proposed. Longer batteries 
may take as long as 9 hours and brief batteries as little 
as 1 - 2 hours. Further, the absence of local popula-
tion norms may limit their utility.16 Work to develop 
brief, normed bedside tests is underway (Singh et al. 
– unpublished data) focusing on the separate domains 
of memory and recall, attention and working memory, 
speed of information processing, executive function-
ing, and motor abnormalities. We have collected popu-
lation norms for the following bedside tests: digit span 
forward, digit span backwards, trail making test A and 
trail making test B. While these tests require training 
to conduct and are likely to be beyond the reach of 
a busy primary care HIV clinical service, they have an 
important role to play as part of specialist referral to 
diagnose HAND. 
antiRetROViRal tHeRaPY
HAART has lowered the incidence of HAND and im-
proved patient outcomes, but HAART is not universally 
successful in reversing or preventing HAND.1  While 
HAART can effectively suppress viral replication in the 
systemic circulation, its pharmacodynamics and effects 
on the virus in the CNS are less clear. ARVs, especially 
protease inhibitors, do not cross the blood-brain bar-
rier easily and do not achieve significant levels in the 
CSF. There is some evidence that CNS-penetrating 
HAART (e.g. abacavir and zidovudine) may be effective 
in improving neuropsychological functioning.8,17 Grow-
ing evidence suggests that for milder neurocognitive 
disorders the use of antiretrovirals may slow progres-
sion or at least prevent severe forms of HAND. 
However, owing to the lack of conclusive evidence that 
HAART can prevent or reverse neurological damage 
caused by HIV, the role of initiating HAART in asymp-
tomatic individuals is undefined.
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